FDA delays decision on Moderna's COVID-19 vaccine for adolescents
CBSN
U.S. regulators are delaying their decision on Moderna's COVID-19 vaccine for 12- to 17-year-olds while they study the rare risk of heart inflammation, the company said Sunday.
The U.S. Food and Drug Administration told the company Friday evening that its review could last until January, Moderna said.
The company also said it will delay filing a request for emergency-use authorization of a lower dose of the vaccine for 6- to 11-year-olds.

The Trump administration deployed ICE and other Homeland Security agents to 14 of the nation's airports on Monday to help shuttle passengers through overcrowded TSA checkpoints. In one airport, the security line wait-time was up to six hours. Nicole Sganga and Kaia Hubbard contributed to this report. In:












